<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Aggressive chemotherapy of advanced <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) evolving from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:hpo ids='HP_0011011'>subacute</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> has usually been associated with low complete remission (CR) rates, a high incidence of early <z:hpo ids='HP_0011420'>death</z:hpo>, and low disease-free survival </plain></SENT>
<SENT sid="1" pm="."><plain>We therefore have initiated a phase-III trial of aggressive chemotherapy consisting of <z:chebi fb="0" ids="42068">idarubicin</z:chebi>, <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi>, and <z:chebi fb="0" ids="4911">VP-16</z:chebi> to improve the CR rate </plain></SENT>
<SENT sid="2" pm="."><plain>Each chemotherapy cycle is followed by G-CSF to accelerate neutrophil recovery and to reduce the incidence of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Until now, 19 patients with high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> have been entered </plain></SENT>
<SENT sid="4" pm="."><plain>The CR rate is 47%, with only one <z:hpo ids='HP_0011420'>death</z:hpo> during induction </plain></SENT>
<SENT sid="5" pm="."><plain>Patients achieving CR are randomized to receive either high-dose or low-dose interleukin-2 to eliminate residual leukemic cells and to prolong the duration of remission </plain></SENT>
</text></document>